|
1
|
Wu Y, Jing Z, Deng D, Yan J, Liu M, Li L, Zuo Y, Wu W, Hu Q, Xie Y. Dkk-1-TNF-α crosstalk regulates MC3T3E1 pre-osteoblast proliferation and differentiation under mechanical stress through the ERK signaling pathway. Mol Cell Biochem 2023; 478:2191-2206. [PMID: 36640256 DOI: 10.1007/s11010-022-04645-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Accepted: 12/15/2022] [Indexed: 01/15/2023]
Abstract
The study aims to explore the role of the ERK signaling pathway in the crosstalk between Dkk-1 and TNF-α in MC3T3E1 pre-osteoblasts under cyclic tensile/compressive stress. A forced four-point bending system was used to apply cyclic uniaxial tensile/compressive strain (2000 μ, 0.5 Hz) to MC3T3E1 cells. Dkk-1 and TNF-α expression were upregulated in MC3T3E1 cells under compressive strain. Cell proliferation, the cell cycle, osteogenesis-related gene (Wnt5a, Runx2, Osterix) expression, β-catenin expression, and the p-ERK/ERK ratio were significantly enhanced, whereas apoptosis, the RANKL/OPG ratio, and TNF-α expression were significantly attenuated, by Dkk-1 silencing. Dkk-1 expression increased and the effects of Dkk-1 silencing were reversed when exogenous TNF-α was added. Mechanically, TNF-α crosstalked with Dkk-1 through ERK signaling in MC3T3E1 cells. ERK signaling blockade impaired Dkk-1-induced TNF-α expression and TNF-α-mediated Dkk-1 expression. Dkk-1 and TNF-α crosstalked, partially through ERK signaling, in MC3T3E1 cells under compressive/tensile strain, synergistically modulating various biological behaviors of the cells. These findings not only provide mechanical insight into the cellular events and molecular regulation of orthodontic tooth movement (OTM), but also aid the development of novel strategies to accelerate OTM.
Collapse
Affiliation(s)
- Yeke Wu
- Department of Stomatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China
| | - Zheng Jing
- College of Stomatology, Chongqing Medical University, Chongqing, People's Republic of China
| | - Disi Deng
- Department of Gynaecology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China
| | - Jin Yan
- Department of Gynaecology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China
| | - Min Liu
- Department of Gynaecology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China
| | - Li Li
- Department of Radiology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China
| | - Yuling Zuo
- Department of Stomatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China
| | - Wenbin Wu
- Department of Geriatrics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China
| | - Qiongying Hu
- Department of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, #39 Shierqiao Rd, Chengdu, 610072, People's Republic of China.
| | - Yunfei Xie
- Department of Nuclear Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, People's Republic of China.
| |
Collapse
|
|
2
|
Lu H, Pundole X, Lee HC. The role of bone-modifying agents in myeloma bone disease. JBMR Plus 2021; 5:e10518. [PMID: 34368608 PMCID: PMC8328802 DOI: 10.1002/jbm4.10518] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 05/13/2021] [Accepted: 05/19/2021] [Indexed: 01/23/2023] Open
Abstract
Bone disease is common in patients with multiple myeloma (MM), which manifests as bone pain and skeletal-related events (SREs) such as pathological fractures and spinal cord compression. Myeloma bone disease (MBD) can adversely affect the quality of life of patients and have negative effects on morbidity and mortality. The pathogenesis of MBD is complex, and several factors are involved in the dysregulation of bone metabolism and uncoupling of bone remodeling, which result in net bone loss and devastating SREs. Broadly speaking, elevated osteoclast activity, suppressed osteoblast activity, and an aberrant marrow microenvironment play a role in MBD. Interaction of MM cells with the main bone cell osteocytes also promote further bone destruction. This review focuses on the role of bone-modifying agents in the prevention and treatment of MBD. The mainstay of MBD prevention are antiresorptive agents, bisphosphonates and denosumab. However, these agents do not play a direct role in bone formation and repair of existing MBD. Newer agents with anabolic effects such as anti-sclerostin antibodies, parathyroid hormone, anti-Dickkopf-1 antibodies, and others have shown potential in repair of MBD lesions. With the development of several new agents, the treatment landscape of MBD is likely to evolve in the coming years. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Huifang Lu
- Department of General Internal Medicine Section of Rheumatology and Clinical Immunology Houston Texas USA
| | - Xerxes Pundole
- Department of Health Services Research The University of Texas MD Anderson Cancer Center Houston Texas USA.,Present address: Amgen Inc. Thousand Oaks CA USA
| | - Hans C Lee
- Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Houston Texas USA
| |
Collapse
|
|
3
|
|
|
4
|
Cucchi D, Menon A, Galliera E, Messina C, Zanini B, Marazzi MG, Massaccesi L, Compagnoni R, Corsi Romanelli MM, Randelli P. A Prospective Assessment of Periprosthetic Bone Mineral Density and Osteoimmunological Biomarkers Variations After Total Knee Replacement Surgery. J Clin Densitom 2019; 22:86-95. [PMID: 30072203 DOI: 10.1016/j.jocd.2018.05.039] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Revised: 05/21/2018] [Accepted: 05/21/2018] [Indexed: 12/12/2022]
Abstract
Aseptic loosening is a major cause of premature failure of total knee replacement (TKR). Variations in periprosthetic bone mineral density (BMD) and osteoimmunological biomarkers levels could help to quantify prosthesis osteointegration and predict early aseptic loosening. The gene expression of 5 selected osteoimmunological biomarkers was evaluated in tibial plateau bone biopsies by real-time polymerase chain reaction and changes in their serum levels after TKR were prospectively evaluated with enzyme-linked immunosorbent assay for 1 yr after surgery. These variations were correlated to changes in periprosthetic BMD. Sixteen patients were evaluated. A statistically significant decrease in serum levels of Sclerostin (p = 0.0135) was observed immediately after surgery. A specular pattern was observed between dickkopf-related protein 1 and osteoprotegerin expression. No statistically significant changes were detectable in the other study biomarkers. Periprosthetic BMD did not change significantly across the duration of the follow-up. Prosthetic knee surgery has an impact on bone remodeling, in particular on sclerostin expression. Although not showing statistically significant changes, in the patterns of dickkopf-related protein 1, osteoprotegerin, and the ligand of the receptor activator of nuclear factor kappa-B symmetries and correspondences related to the biological activities of these proteins could be identified. Variation in osteoimmunological biomarkers after TKR surgery can help in quantifying prosthesis osteointegration.
Collapse
Affiliation(s)
- Davide Cucchi
- Department of Orthopaedics and Trauma Surgery, Universitätsklinikum Bonn, Bonn 53127, Germany; Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan 20133, Italy.
| | - Alessandra Menon
- Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan 20133, Italy; 1° Clinica Ortopedica, ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milan 20122, Italy
| | - Emanuela Galliera
- Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan 20133, Italy; IRCCS Galeazzi Orthopaedic Institute, Milan 20161, Italy
| | - Carmelo Messina
- Department of Diagnostic and Interventional Radiology, IRCCS Galeazzi Orthopaedic Institute, Milan 20161, Italy
| | - Beatrice Zanini
- 1° Clinica Ortopedica, ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milan 20122, Italy
| | - Monica Gioia Marazzi
- Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan 20133, Italy
| | - Luca Massaccesi
- Department of Biomedical, Surgical and Oral Science, Università degli Studi di Milano, Milan 20133, Italy
| | - Riccardo Compagnoni
- Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan 20133, Italy; 1° Clinica Ortopedica, ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milan 20122, Italy
| | - Massimiliano M Corsi Romanelli
- Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan 20133, Italy; U.O.C SMEL-1 Patologia Clinica, IRCCS Policlinico San Donato, Milan 20097, Italy
| | - Pietro Randelli
- Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan 20133, Italy; 1° Clinica Ortopedica, ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milan 20122, Italy
| |
Collapse
|
|
5
|
Galliera E, Ragone V, Marazzi MG, Selmin F, Banci L, Corsi Romanelli MM. Vitamin E-stabilized UHMWPE: Biological response on human osteoblasts to wear debris. Clin Chim Acta 2018; 486:18-25. [DOI: 10.1016/j.cca.2018.07.012] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2018] [Accepted: 07/09/2018] [Indexed: 12/31/2022]
|
|
6
|
Ring ES, Lawson MA, Snowden JA, Jolley I, Chantry AD. New agents in the Treatment of Myeloma Bone Disease. Calcif Tissue Int 2018; 102:196-209. [PMID: 29098361 PMCID: PMC5805798 DOI: 10.1007/s00223-017-0351-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Accepted: 10/19/2017] [Indexed: 12/17/2022]
Abstract
Patients with multiple myeloma develop a devastating bone disease driven by the uncoupling of bone remodelling, excess osteoclastic bone resorption and diminished osteoblastic bone formation. The bone phenotype is typified by focal osteolytic lesions leading to pathological fractures, hypercalcaemia and other catastrophic bone events such as spinal cord compression. This causes bone pain, impaired functional status, decreased quality of life and increased mortality. Early in the disease, malignant plasma cells occupy a niche environment that encompasses their interaction with other key cellular components of the bone marrow microenvironment. Through these interactions, osteoclast-activating factors and osteoblast inhibitory factors are produced, which together uncouple the dynamic process of bone remodelling, leading to net bone loss and focal osteolytic lesions. Current management includes antiresorptive therapies, i.e. bisphosphonates, palliative support and orthopaedic interventions. Bisphosphonates are the mainstay of treatment for myeloma bone disease (MBD), but are only partially effective and do have some significant disadvantages; for example, they do not lead to the repair of existing bone destruction. Thus, newer agents to prevent bone destruction and also promote bone formation and repair existing lesions are warranted. This review summarises novel ways that MBD is being therapeutically targeted.
Collapse
Affiliation(s)
- Elizabeth S Ring
- Department of Oncology and Metabolism, Faculty of Medicine, Dentistry and Health, The University of Sheffield Medical School, Beech Hill Road, Sheffield, South Yorkshire, S10 2RX, UK.
| | - Michelle A Lawson
- Sheffield Myeloma Research Team, Department of Oncology and Metabolism, Mellanby Bone Centre, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
| | - John A Snowden
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - Ingrid Jolley
- Department of Oncology and Metabolism, Faculty of Medicine, Dentistry and Health, The University of Sheffield Medical School, Beech Hill Road, Sheffield, South Yorkshire, S10 2RX, UK
- Department of Radiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - Andrew D Chantry
- Department of Oncology and Metabolism, Faculty of Medicine, Dentistry and Health, The University of Sheffield Medical School, Beech Hill Road, Sheffield, South Yorkshire, S10 2RX, UK
- Sheffield Myeloma Research Team, Department of Oncology and Metabolism, Mellanby Bone Centre, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
- Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| |
Collapse
|
|
7
|
Abstract
[This corrects the article DOI: 10.1097/MD.0000000000003291.][This corrects the article DOI: 10.1097/MD.0000000000003731.][This corrects the article DOI: 10.1097/MD.0000000000003791.][This corrects the article DOI: 10.1097/MD.0000000000003805.][This corrects the article DOI: 10.1097/MD.0000000000003827.][This corrects the article DOI: 10.1097/MD.0000000000003863.][This corrects the article DOI: 10.1097/MD.0000000000003878.][This corrects the article DOI: 10.1097/MD.0000000000003879.][This corrects the article DOI: 10.1097/MD.0000000000003884.][This corrects the article DOI: 10.1097/MD.0000000000003900.][This corrects the article DOI: 10.1097/MD.0000000000003513.][This corrects the article DOI: 10.1097/MD.0000000000003631.][This corrects the article DOI: 10.1097/MD.0000000000003644.][This corrects the article DOI: 10.1097/MD.0000000000003692.][This corrects the article DOI: 10.1097/MD.0000000000003701.][This corrects the article DOI: 10.1097/MD.0000000000003706.][This corrects the article DOI: 10.1097/MD.0000000000003712.][This corrects the article DOI: 10.1097/MD.0000000000003767.][This corrects the article DOI: 10.1097/MD.0000000000003781.][This corrects the article DOI: 10.1097/MD.0000000000003808.][This corrects the article DOI: 10.1097/MD.0000000000003831.][This corrects the article DOI: 10.1097/MD.0000000000003837.][This corrects the article DOI: 10.1097/MD.0000000000003839.][This corrects the article DOI: 10.1097/MD.0000000000003842.][This corrects the article DOI: 10.1097/MD.0000000000003843.][This corrects the article DOI: 10.1097/MD.0000000000003847.][This corrects the article DOI: 10.1097/MD.0000000000003848.][This corrects the article DOI: 10.1097/MD.0000000000003850.][This corrects the article DOI: 10.1097/MD.0000000000003861.][This corrects the article DOI: 10.1097/MD.0000000000003862.][This corrects the article DOI: 10.1097/MD.0000000000003864.][This corrects the article DOI: 10.1097/MD.0000000000003866.][This corrects the article DOI: 10.1097/MD.0000000000003871.][This corrects the article DOI: 10.1097/MD.0000000000003872.][This corrects the article DOI: 10.1097/MD.0000000000003880.][This corrects the article DOI: 10.1097/MD.0000000000003878.][This corrects the article DOI: 10.1097/MD.0000000000003873.][This corrects the article DOI: 10.1097/MD.0000000000003876.][This corrects the article DOI: 10.1097/MD.0000000000003879.][This corrects the article DOI: 10.1097/MD.0000000000003881.][This corrects the article DOI: 10.1097/MD.0000000000003884.][This corrects the article DOI: 10.1097/MD.0000000000003885.][This corrects the article DOI: 10.1097/MD.0000000000003888.][This corrects the article DOI: 10.1097/MD.0000000000003889.][This corrects the article DOI: 10.1097/MD.0000000000003891.][This corrects the article DOI: 10.1097/MD.0000000000003893.][This corrects the article DOI: 10.1097/MD.0000000000003894.][This corrects the article DOI: 10.1097/MD.0000000000003897.][This corrects the article DOI: 10.1097/MD.0000000000003899.][This corrects the article DOI: 10.1097/MD.0000000000003900.][This corrects the article DOI: 10.1097/MD.0000000000003901.][This corrects the article DOI: 10.1097/MD.0000000000003902.][This corrects the article DOI: 10.1097/MD.0000000000003903.][This corrects the article DOI: 10.1097/MD.0000000000003904.][This corrects the article DOI: 10.1097/MD.0000000000003908.][This corrects the article DOI: 10.1097/MD.0000000000003910.][This corrects the article DOI: 10.1097/MD.0000000000003912.][This corrects the article DOI: 10.1097/MD.0000000000003916.][This corrects the article DOI: 10.1097/MD.0000000000003917.][This corrects the article DOI: 10.1097/MD.0000000000003918.][This corrects the article DOI: 10.1097/MD.0000000000003920.][This corrects the article DOI: 10.1097/MD.0000000000003921.][This corrects the article DOI: 10.1097/MD.0000000000003923.][This corrects the article DOI: 10.1097/MD.0000000000003924.][This corrects the article DOI: 10.1097/MD.0000000000003925.][This corrects the article DOI: 10.1097/MD.0000000000003934.][This corrects the article DOI: 10.1097/MD.0000000000003941.][This corrects the article DOI: 10.1097/MD.0000000000003944.][This corrects the article DOI: 10.1097/MD.0000000000003970.].
Collapse
|